Prostate Cancer International is
for 2011 by Great NonProfits
Perspective Confidentiality Disclosure Reliability Courtesy
An article in the June issue of the Canadian Urological Association Journal offers preliminary evidence from a randomized clinical trial that men treated for 6 months with a short-acting LHRH agonist may recover normal serum testosterone (T) levels faster than those treated for the same time with a long-acting LHRH agonist.
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: LHRH agonist, long-acting, recovery, serum, short-acting, testosterone | 2 Comments »
There are two potentially good reasons for a patient who is receiving treatment with an LHRH agonist to switch from one product to another: the first is because he is having a problem with the adverse effects of his initial LHRH therapy; the second is because he has a rising PSA on the initial LHRH [...]
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: LHRH agonist, outcome, switch | 1 Comment »
As if it wasn’t long enough already, the list of adverse events “associated with” the use of androgen deprivation therapy (ADT) in the treatment of prostate cancer is growing.
Filed under: Living with Prostate Cancer, Management, Treatment, Uncategorized | Tagged: ADT, adverse effect, androgen deprivation, colorectal, LHRH agonist, orchiectomy | 4 Comments »
Financial disincentives related to prescribing of LHRH agonists introduced in 2003 have clearly been associated with changes in actual physician prescriptions for drugs like Lupron and Zoladex in the immediately following years.
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: appropriate use, cost, finance, incentive, LHRH agonist, Medicare | 3 Comments »
While it has never been categorically proven that adding an oral antiandrogen like flutamide or bicalutamide (Casodex) to injections of LHRH agonists (e.g., leuprolide actetate) improves overall patient survival, there had been little doubt in people’s minds that giving an antiandrogen for a week or two before a first LHRH agonist injection prevented the problem [...]
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: antiandrogen, flare, LHRH agonist, testosterone | 1 Comment »
Today’s news reports address such items as: Finasteride in the prevention of prostate cancer Nitric oxide treatment in men with a rising PSA after first-line therapy Decreased use of LHRH agonist therapy since 2003
Filed under: Drugs in development, Management, Prevention, Treatment | Tagged: finasteride, LHRH agonist, nitric oxide, Prevention, risk | Leave a Comment »
This morning’s news reports address: Patterns of use of PSA and DRE testing in the USA The value of ADT in men receiving combined brachytherapy + EBRT Skeletal and cardiovascular adverse effects of ADT LHRH agonist treatment and effects on LHRH agonist receptors
Filed under: Diagnosis, Drugs in development, Management, Risk, Treatment | Tagged: ADT, androgen deprivation, DRE, LHRH agonist, mechanism of action, pattens of use, PSA | Leave a Comment »
Today’s news reports cover items on: The feasibility of gene expression analysis and prostate cancer prognosis The potential of color Döppler ultrasound to assess prostate cancer risk Radical perineal prostatectomy and quality of life in Japanese patients Outcomes and satisfaction with treatment among patients < 65 years of age LHRH agonist therapy and cognitive dysfunction
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: cognitive dysfunction, color Döppler ultrasound, gene expression, Japanese, LHRH agonist, outcome, perineal prostatectomy, prognosis, risk, satisfaction | Leave a Comment »
Today’s news items deal with timing of hormone therapy for men with lymph node-positive prostate cancer, the impact of adjuvant LHRH agonist therapy on cardiovascular mortality in men receiving radiotherapy for locally advanced prostate cancer, and the status of the epothilones in treatment of metastatic prostate cancer.
Filed under: Drugs in development, Management, Treatment, Uncategorized | Tagged: cardiovascular mortality, epothilone, LHRH agonist | Leave a Comment »
Search for new and
ongoing trials on the
CTAG PCa web site